When an HLA-matched sibling is not available and nontransplant approaches have been ineffective, transplantation of hematopoietic stem cells from an unrelated donor can effect a cure in some patients with chronic myelogenous leukemia. Even when successful, however, transplantation is a rigorous and prolonged process whose complications include infection and graft-versus-host disease. Improvements in hematopoietic stem-cell transplantation as well as innovative nontransplant approaches may improve the outcome in these patients.
Bibliographical noteFunding Information:
Dr. McGiave Is C. J. Watson Professor of Medicine and Director, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical Schooi--Minneapolis, and Associate Director for Experimental Therapeutics, Uni-'lllrsity of Minnesota Cancer Canter. His work is supported by NIH grants PO I CA6S.ol93 and P30CA77598. Dr. Cassileth is Professor and Chair, Division of Hematology-Oncology, Department of Medicine, University of Miami School of Medicine.
Copyright 2020 Elsevier B.V., All rights reserved.